Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 28:1:5.
doi: 10.1186/s42466-019-0005-5. eCollection 2019.

Navigating choice in multiple sclerosis management

Ralf A Linker  1 , Andrew Chan  2
Affiliations
Review

Navigating choice in multiple sclerosis management

Ralf A Linker et al. Neurol Res Pract. .

Abstract

Background: With the advent of modern immunotherapies for relapsing-remitting multiple sclerosis (RRMS) and the increasing amount of treatment options on the market, MS has evolved as a treatable disease. Yet, at the same time, new challenges for the treating neurologists arise.

Main body: This review article covers some of these challenges, including when and how to start treatment, treatment monitoring, and finally considerations on what the increasing choice in treatment options brings to disease management and longer-term planning. Among others, these important issues comprise pregnancy, treatment sequencing, switching or even stopping treatment.

Conclusion: The ultimate goal for navigating choices in RRMS management is to choose the right drug for the right patient at the right time Throughout the article, there is a strong focus on practical aspects and individual decision making in MS to meet the concept of personalized medicine.

Keywords: Disease management; Immunomodulation; MS therapy; Personalized medicine; Treatment monitoring.

PubMed Disclaimer

Conflict of interest statement

Competing interestsRAL received compensation for activities with Almirall, Bayer, Biogen, Genzyme, Merck, Novartis, Roche and Teva as well as research support from Biogen and Novartis. AC received research support from Genzyme and Novartis well as personal compensation for activities with Almirall, Bayer, Biogen, Genzyme, Merck, Novartis, Sanofi, and Teva.

References

    1. Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Multiple sclerosis outcome assessments consortium. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Multiple Sclerosis. 2017;23(5):721–733. doi: 10.1177/1352458517690821. - DOI - PMC - PubMed
    1. Bevan CJ, Cree BA. Disease, activity free status: A new end point for a new era in multiple sclerosis clinical research? Journal of the American Medical Assocation Neurology. 2014;1(3):269–270. - PubMed
    1. Biberacher V, Schmidt P, Keshavan A, Boucard CC, Righart R, Sämann P, Preibisch C, Fröbel D, Aly L, Hemmer B, Zimmer C, Henry RG, Mühlau M. Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. Neuroimage. 2016;142:188–197. doi: 10.1016/j.neuroimage.2016.07.035. - DOI - PubMed
    1. Bsteh G, Feige J, Ehling R, Auer M, Hegen H, Di Pauli F, Deisenhammer F, Reindl M, Berger T. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors. Multiple Sclerosis. 2017;23(9):1241–1241. doi: 10.1177/1352458516675751. - DOI - PubMed
    1. Capra R, Cordioli C, Rasia S, Gallo F, Signori A, Sormani MP. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Multiple Sclerosis. 2017;23(13):1757–1761. doi: 10.1177/1352458516687402. - DOI - PubMed

LinkOut - more resources